The 14 Billion Dose COVID-19 Manufacturing Challenge
mRNA Vaccines Leading The Way
Executive Summary
Manufacturing COVID-19 vaccines at unprecedented speed and scale is 2021’s biggest challenge – and mRNA platforms are emerging as the leaders, living up to their promise as the ideal technology for pandemic preparedness.
You may also be interested in...
Pfizer Rose To The COVID-19 Challenge And The Stars Aligned
Pfizer moved aggressively and early as COVID-19 became a global health threat, and now the company, with its partner BioNTech, is the first to secure an emergency use authorization for a COVID vaccine from the US FDA.
Acceleron To Be Next M&A Target With Rumored $11bn Deal
The Cambridge, MA-based biotech has one blockbuster-tipped drug already on the market, with another in pivotal studies.
Another Activist Investor Joins Calls For GSK Leadership Review
A second activist investor has called for GSK to consider replacing Emma Walmsley as CEO, and has underlined competitive threats to a key pipeline candidate.